Do beta-blockers reduce morbidity and mortality in patients with class II through IV heart failure?
Beta-blockers are a foundational therapy that reduces morbidity and mortality in patients with symptomatic (class II-IV) heart failure.
Tested in more than 10,000 patients, beta-blockers reduce morbidity and mortality in class II through IV heart failure. Along with angiotensin-converting enzyme inhibitors, digoxin, and diuretics, beta-blockers have strengthened the armamentarium to improve clinical outcomes of heart failure patients. The science supporting beta-blockers must be translated into practice safely and rationally if the agents are to achieve their full potential.
Foody et al. (Wed,) studied this question.